TORONTO Premier Doug Ford warned that turbulent waters are ahead in the fight against COVID-19 on Sunday as Ontario set yet another single-day high for new diagnoses.
He said the health-care system is on the brink of being overwhelmed as cases of the novel coronavirus continue to soar in swaths of the province. We need to band together; we need to stick together, Ford said in a pre-recorded video posted to Twitter. We re going to see some real turbulent waters in the next couple months.
He said that while officials are working to vaccinate people quickly, mass inoculation won t happen until April, May and June.
(1)
TORONTO, Jan. 12, 2021 (GLOBE NEWSWIRE) POINT Biopharma Inc. (POINT), a radiopharmaceutical company dedicated to bringing the many benefits of precision radioligand therapy to cancer patients, today announced that it has signed a licensing and commercialization agreement with CanProbe for exclusive rights to Lutetium - 177 Octreotate (Lu-DOTATATE) for the treatment of neuroendocrine cancer. CanProbe, a joint venture between the University Health Network (UHN) and the Centre for Probe Development and Commercialization (CPDC), developed Lu-DOTATATE as it is being used in 167 neuroendocrine tumor (NET) patients in a 180-patient trial with enrollment completed. CanProbe s NET clinical program has helped many patients in Ontario who previously had no other options for treatment, says Dr. Joe McCann, Chief Executive Officer of POINT Biopharma. We are excited to extend access to this treatment by leveraging CanProbe s intellectual property to seek regulatory approvals, with the
Toronto Life and FASHION magazine that includes access to intimate pop-up food & and drink experiences, weekly deals and promotions from top Toronto brands, and virtual fireside chats and workshops with some of the city’s most interesting characters.
We caught up with long-time TL Insider Pete Poon about his experience with the membership, the digital shift and what he’s looking forward to this year.
Do you have any New Year’s resolutions for 2021?
My goal is to rally in support of local business especially BIPOC-owned businesses in Toronto. I think it’s important to remember that our local shops and services still need our support in the new year.
Next Phase Of COVID Vaccinations Could Start Soon iheart.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from iheart.com Daily Mail and Mail on Sunday newspapers.
POINT Biopharma
POINT Biopharma Signs Exclusive License Agreement with CanProbe for the Commercialization of a Neuroendocrine Tumor Treatment
POINT Biopharma Signs Exclusive License Agreement with CanProbe for the Commercialization of a Neuroendocrine Tumor Treatment
TORONTO, Jan. 12, 2021 (GLOBE NEWSWIRE) POINT Biopharma Inc. (POINT), a radiopharmaceutical company dedicated to bringing the many benefits of precision radioligand therapy to cancer patients, today announced that it has signed a licensing and commercialization agreement with CanProbe for exclusive rights to Lutetium – 177 Octreotate (Lu-DOTATATE) for the treatment of neuroendocrine cancer. CanProbe, a joint venture between the University Health Network (UHN) and the Centre for Probe Development and Commercialization (CPDC), developed Lu-DOTATATE as it is being used in 167 neuroendocrine tumor (NET) patients in a 180-patient trial with enrollment completed.